Discovery/Development of Novel Therapeutics for Eukaryotic Pathogens (R21/R33)

Funding Agency:
National Institutes of Health

The purpose of this FOA is to solicit applications to support early stage translational research focused on the discovery and development of novel therapeutics against select eukaryotic pathogens. 

Deadlines:

  • Letter of Intent Due Date(s): January 10, 2016
  • Application Due Date(s): February 10, 2016, by 5:00 PM local time of applicant organization.

​RFA-AI-15-054 Expiration Date February 11, 2016

Agency Website

Amount

$275,000

Amount Description

Application budgets are limited to $275,000 in direct costs over the two-year project period, with a maximum of $200,000 in direct costs allowed in any single year. The R33 award phase is limited to $300,000 in direct costs per year.

Funding Type

Grant

Eligibility

Faculty

Category

Medical
Medical - Translational

External Deadline

February 10, 2016